Skip to main content

Table 1 Patients’ characteristics at baseline

From: The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial

  All patients
N = 92
MTX+plac
n = 50
MTX+pred
n = 42
% female 59 56 62
Age 57 (47–65) 54 (46–65) 58 (47–67)
Smoking, as number of cigarettes per day 0 (0–5) 0 (0–0.5) 0 (0–5)
RF status, % positive 63 70 56
HAQ score, 0–3 1.1 (0.63–1.6) 1.2 (0.63–1.6) 1.1 (0.63–1.5)
General health VAS, 0–10 5.0 (2.7–6.7) 5.1 (3.6–6.6) 4.7 (2.2–6.7)
TJC28 10 (6–17) 9.5 (6–13) 12 (5–18)
SJC28 11 (7–15) 11 (7–15) 11 (6–15)
ESR mm/h 31 (19–44) 29 (19–43) 31 (18–45)
CRP mg/L 16 (2.7–41) 16 (5.5–42) 16 (1.9–37)
DAS28 5.6 (4.9–6.6) 5.6 (5–6.3) 5.6 (4.1–6.9)
MBDA score, 1–100 51 (39–71) 54 (40–72) 49 (40–70)
  1. No statistically significant differences in baseline characteristic between MTX+plac and MTX+pred groups. Values are median (interquartile range) or percentage
  2. RF, rheumatoid factor (RF status was available for 82 of 92, 43 of 50, and 39 of 42 patients, respectively); MTX, methotrexate; HAQ, health assessment questionnaire; VAS, visual analogue scale general health; TJC28, tender joint count assessing 28 joints; SJC28, swollen joint count assessing 28 joints; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; DAS28, 28-joint-based disease activity score; MBDA, multi-biomarker disease activity; higher scores of HAQ, VAS, and MBDA score reflect worse scores; MTX+plac, the methotrexate and placebo strategy; MTX+pred the methotrexate and prednisone strategy